Boston Scientific (NYSE:BSX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, July 24th. Analysts expect the company to announce earnings of $0.58 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. On average, analysts expect Boston Scientific to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Boston Scientific Trading Up 0.2 %
NYSE BSX opened at $78.14 on Wednesday. The firm has a market capitalization of $114.64 billion, a PE ratio of 65.66, a price-to-earnings-growth ratio of 2.67 and a beta of 0.78. The business’s 50-day moving average price is $76.01 and its two-hundred day moving average price is $69.43. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific has a 12 month low of $48.35 and a 12 month high of $78.98.
Insiders Place Their Bets
In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares in the company, valued at approximately $3,316,788.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,259 shares of company stock valued at $5,344,014. Corporate insiders own 0.50% of the company’s stock.
Analyst Upgrades and Downgrades
BSX has been the subject of a number of recent analyst reports. Wells Fargo & Company increased their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Truist Financial increased their price objective on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday. Mizuho boosted their target price on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, May 15th. Barclays increased their price target on Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Finally, Royal Bank of Canada boosted their price objective on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $82.29.
Read Our Latest Research Report on Boston Scientific
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Articles
Receive News & Ratings for Boston Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boston Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.